increasingly being placed on active surveillance, 8 given that the reduction in death from prostate cancer (hazard ratio, 0.63; 95% CI, 0.36 to 1.09) in the Prostate Cancer Intervention versus Observation Trial (PIVOT) only trended toward significance (P = 0.09). 9 However, the increasing use of surveillance is already of potential concern, considering that men enrolled in PIVOT had a shorter life expectancy owing to coexisting disease than men of similar age entered into the Surveillance, Epidemiology, and End Results database.
increasingly being placed on active surveillance, 8 given that the reduction in death from prostate cancer (hazard ratio, 0.63; 95% CI, 0.36 to 1.09) in the Prostate Cancer Intervention versus Observation Trial (PIVOT) only trended toward significance (P = 0.09). 9 However, the increasing use of surveillance is already of potential concern, considering that men enrolled in PIVOT had a shorter life expectancy owing to coexisting disease than men of similar age entered into the Surveillance, Epidemiology, and End Results database. 10 Finally, a trend favoring radiation and shortcourse androgen-deprivation therapy over surgery was observed. Specifically, the point estimate for the hazard ratio for death from prostate cancer when comparing these two treatments was 0.80 (95% CI, 0.22 to 2.99). If this trend becomes significant, then one may consider radiation and androgen-deprivation therapy as a preferred option for otherwise healthy men 65 years of age or older with early prostate cancer for whom treatment as compared with monitoring may be more effective (P = 0.09 for interaction) in reducing death from prostate cancer.
For today, we can conclude on the basis of level 1 evidence 2 that PSA monitoring, as compared with treatment of early prostate cancer, leads to increased metastasis. Therefore, if a man wishes to avoid metastatic prostate cancer and the side effects of its treatment, 3 monitoring should be considered only if he has life-shortening coexisting disease such that his life expectancy is less than the 10-year median follow-up of the current study. 2 In addition, given no significant difference in death due to prostate cancer with surgery versus radiation and short-course androgen-deprivation therapy, men with low-risk or intermediate-risk 1 prostate cancer should feel free to select a treatment approach using the data on health-related quality of life 3 and without fear of possibly selecting a less effective cancer therapy.
Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org. 
Solving the Problem of Overdiagnosis
My patients' fear of breast cancer is palpable. I see them fret over whether or not to have a mammogram, worry about false positive abnormalities, and struggle to pay for diagnostic evaluations for which they are not reimbursed. This collateral damage of screening is obvious to clinicians. However, increasing evidence now indicates a less obvious outcome of cancer screening -overdiagnosis of diseases that would never cause symptoms or death. The presence and effects of overdiagnosis are less tangible, buried in population statistics rather than patient encounters.
Overdiagnosis of breast cancer has been suggested on the basis of multiple studies that used different designs and approaches and is acknowl-edged by national organizations such as the American Cancer Society and the U.S. Preventive Services Task Force.
1,2 Overdiagnosis of other cancers has also been noted. Overdiagnosis of thyroid cancer accompanied the introduction of ultrasound screening, 3 and overdiagnosis of melanoma accompanied widespread screening for skin cancer. 4 Overdiagnosis of lung cancer associated with low-dose computed tomographic screening examinations and overdiagnosis of prostate cancer after prostate-specific antigen testing have been reported. 5, 6 In this issue of the Journal, Welch et al. 7 add to the growing literature regarding overdiagnosis by describing the shift in size distribution of breastcancer tumors since screening mammography was introduced in the United States. When data from women who received a diagnosis of breast cancer in the late 1970s were compared with data from those who received a diagnosis in the early 2000s, the incidence of large tumors decreased by 30 cases of cancer per 100,000 women (which suggests that screening has had the desired effect), and the incidence of small tumors increased by 162 cases of cancer per 100,000 women. Assuming that the underlying burden of clinically meaningful breast cancer was unchanged, these data suggest extensive overdiagnosis of small tumors (i.e., only 30 of the 162 additional small tumors per 100,000 women that were diagnosed were expected to become large). Welch et al. also propose that the reduction in breast-cancer mortality for large tumors after the introduction of screening mammography reflected improved cancer treatment more than screening.
Although Welch et al. present powerful data on a large number of women in a very clear fashion, they also rely on data with extensive missing values, make assumptions about underlying disease burden that cannot be verified, and acknowledge that their estimates are imprecise. Rather than focusing on statistical issues and study design, we should move forward by agreeing that overdiagnosis does occur, even though the exact percentage of overdiagnosed cases remains unknown.
Some consider overdiagnosis to be an intractable problem. No single approach will adequately address the issue. Instead, a multilevel approach ranging from research and education at the population level to intensified focus at the patient level is needed (Table 1) . One way to reduce overdiagnosis is targeted, precision screening of persons who have a higher risk of breast cancer rather than screening large populations in which the majority of persons are at a lower risk for harmful disease.
Health care system incentives and feedback systems also require attention. The threat of medical malpractice litigation coupled with financial incentives to do more can conflict with our goal of helping patients. We get credit for curing disease that never would have harmed the patient. We receive positive feedback from patients thanking us for "saving my life," alarming feedback from patients with "missed diagnoses," and no feedback at all from patients whose cancer was overdiagnosed. The mantras, "All cancers are life-threatening" and "When in doubt, cut it out," require revision.
At the provider level, we need better tools to evaluate medical data and classify findings on the basis of clinical judgment. Previous research has documented extensive diagnostic variability among radiologists in their interpretation of mammograms and among pathologists in their interpretation of breast-biopsy specimens. 8, 9 We are using archaic disease-classification systems with inadequate vetting and defective nosologic boundaries. Diagnostic thresholds for "abnormality" need to be revised because the middle and lower boundaries of these classification systems have expanded without a clear benefit to patients. Disease-classification systems are often developed by experts on the basis of a small number of ideal cases and are then adopted broadly into clinical practice -a system that is antithetical to the scientific process. The National Academies of Sciences, Engineering, and Medicine recently deemed improvement of the diagnostic process "a moral, professional, and public health imperative."
10 Rigorous analytic methods are required for the development of disease nosologies, and physicians need more sophisticated tools to improve diagnostic precision and accuracy. At the patient level, we need better methods of distinguishing biologically self-limited tumors from harmful tumors that progress.
We must also improve communication regarding overdiagnosis at all levels, from dissemination of scientific findings at a population level to education of patients before they undergo screening. Clinicians face time constraints and lack experience in communicating screening nuances. Better training may help. Building trust in science and medicine starts by taking ownership of all aspects of the screening cascade, including the collateral damage of our well-intentioned efforts.
Disclosure forms provided by the author are available with the full text of this article at NEJM.org.
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